Corvus Pharmaceuticals News

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $

BenzingaApr 10 04:31

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end

GlobeNewswireApr 10 04:01

Cantor Fitzgerald Reiterates Overweight on Corvus Pharma

Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:CRVS) with a Overweight.

BenzingaApr 1 23:16

Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns

TipRanksMar 29 16:25

Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target

Mizuho analyst Graig Suvannavejh maintains Corvus Pharma with a Neutral and maintains $3.5 price target.

Analyst UpgradesMar 28 01:21

Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?

Yahoo FinanceMar 23 00:00

Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns

TipRanksMar 21 14:01

Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Dow JonesMar 20 19:24

Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 to $7.

BenzingaMar 20 19:14

Corvus Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 246.53% Oppenheimer $8 → $7 Maintains Outperform 09/07/2023 98.02% Cantor Fitzgerald → $4 Reite

BenzingaMar 20 19:13

Earnings Call Summary | Corvus Pharmaceuticals(CRVS.US) Q4 2023 Earnings Conference

The following is a summary of the Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript:Financial Performance:Data unavailable.Business Progress:Data unavailable. Please provide the det

Futu NewsMar 20 09:15 · Conference Call

Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2

Corvus Pharmaceuticals (CRVS) said Tuesday it expects to start a phase 1 study of soquelitinib in patients with moderate to severe atopic dermatitis in Q2. Corvus expects to enroll 64 patients who hav

MT NewswiresMar 20 05:32

Corvus Pharma Q4 EPS $(0.14) Misses $(0.12) Estimate

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 33.33 percent increase over losses of $(0.

BenzingaMar 20 04:04

Corvus Pharmaceuticals GAAP EPS of -$0.14 Misses by $0.01

Seeking AlphaMar 20 04:04

Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS

Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS

Dow JonesMar 20 04:04

Corvus Pharmaceuticals 4Q Loss/Shr 14c >CRVS

Corvus Pharmaceuticals 4Q Loss/Shr 14c >CRVS

Dow JonesMar 20 04:02

Corvus Pharmaceuticals 4Q Loss $6.65M >CRVS

Corvus Pharmaceuticals 4Q Loss $6.65M >CRVS

Dow JonesMar 20 04:02

Press Release: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical t

Dow JonesMar 20 04:02

Earnings Scheduled For March 19, 2024

Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. • HUYA (NYSE:HUYA) is likely to repo

BenzingaMar 19 18:06

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on

GlobeNewswireMar 14 04:02